Instantaneous 发表于 2025-3-26 22:52:37
T. Kawaguchi,K. Hishida,M. Maedas may account for as much as 30% of interindividual differences in drug disposition and response. An increasing number of drug target polymorphisms have also been linked to differences in drug response. This chapter reviews some examples of the use of pharmacogenetics in clinical practice. Despite tliaison 发表于 2025-3-27 03:13:23
http://reply.papertrans.cn/19/1884/188315/188315_32.pngexplicit 发表于 2025-3-27 07:41:33
http://reply.papertrans.cn/19/1884/188315/188315_33.png可耕种 发表于 2025-3-27 10:10:26
http://reply.papertrans.cn/19/1884/188315/188315_34.png龙虾 发表于 2025-3-27 16:59:06
R. J. Adrian,D. F. G. Durao,J. H. Whitelaw no FOPP have yet been approved in the US or European pharmaceutical market. This is because of a lack of registration process for the demonstration of pharmaceutical and therapeutic/clinical equivalence. The production of FOPP is a significant opportunity for patients, managed health care providers高原 发表于 2025-3-27 18:04:30
http://reply.papertrans.cn/19/1884/188315/188315_36.pngDefraud 发表于 2025-3-27 23:58:53
Microarray Technology Using Proteins, Cells, and Tissues,analysis. This chapter reviews the current status of protein microarray assays and highlights efforts using cells and tissues on microarrays. These ‘other’ microarrays have the potential to yield highly parallel miniaturized assays that will accelerate drug discovery efforts and facilitate understanding of biological complexity.有节制 发表于 2025-3-28 03:00:23
http://reply.papertrans.cn/19/1884/188315/188315_38.png无脊椎 发表于 2025-3-28 06:50:06
http://image.papertrans.cn/b/image/188315.jpg要素 发表于 2025-3-28 13:54:16
https://doi.org/10.1007/978-3-540-45867-8analysis. This chapter reviews the current status of protein microarray assays and highlights efforts using cells and tissues on microarrays. These ‘other’ microarrays have the potential to yield highly parallel miniaturized assays that will accelerate drug discovery efforts and facilitate understanding of biological complexity.